Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 6 days ago
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Oral anticoagulation may do more harm than good in ESRD patients with atrial fibrillation

26 Mar 2020

Use of oral anticoagulation (OAC) among patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) is low, reveals a study. OAC use does not appear to reduce the risk of stroke or death and is even associated with higher risks of hospitalization for bleeding or intracranial haemorrhage.

Of the 8,410 patients with AF and ESRD included in the analysis, 3,043 (36.2 percent) received OAC at some time during the study period. Propensity scores were used to match 1,519 patients with AF and ESRD on OAC with 3,018 ESRD patients not using OAC.

OAC use did not reduce hospitalization for stroke (hazard ratio [HR], 1.00, 95 percent confidence interval [CI], 0.23–1.35; p=0.097) or death (HR, 1.02, 95 percent CI, 0.94–1.10; p=0.62). Treatment with OAC also correlated with an increased risk of hospitalization for bleeding (HR, 1.26, 95 percent CI, 1.09–1.46; p=0.0017) and intracranial haemorrhage (HR, 1.30, 95 percent CI, 1.07–1.59; p=0.0094).

“Alternative stroke prevention strategies are needed in patients with ESRD and AF,” the authors noted.

Data from Medicare fee-for-service 5-percent claims from 2007 to 2013 were used to analyse treatment and outcomes in a cohort of patients with ESRD and AF. The timing of OAC therapy was determined using prescription drug benefit information.

The authors then compared outcomes including death, all-cause stroke, ischaemic stroke, haemorrhagic stroke and bleeding hospitalizations in ESRD patients treated with or without OAC using Cox proportional hazards modeling.

AF is common in patients with ESRD, according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 6 days ago
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.